BIIB Q2 2018 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q2 2018 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$3.4B+9.0% YoY

Gross Profit

$2.9B87.5% margin

Operating Income

$1.2B36.1% margin

Net Income

$867M25.8% margin

EPS (Diluted)

$4.18

QoQ Revenue Growth

+7.2%

Cash Flow

Operating Cash Flow

$1.1B

Free Cash Flow

$835M

Stock-Based Comp.

$38M

Balance Sheet

Total Assets

$24.0B

Total Liabilities

$11.7B

Stockholders' Equity

$12.3B

Cash & Equivalents

$1.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.4B	$3.1B	+9.0%
Gross Profit	$2.9B	$2.7B	+8.2%
Operating Income	$1.2B	$1.2B	+1.0%
Net Income	$867M	$863M	+0.4%

Revenue Segments

Interferon

$626M41%

TYSABRI product

$467M31%

SPINRAZA

$423M28%

Geographic Segments

UNITED STATES

$1.7B63%

Non-US

$1.0B37%